Investor Relations News Releases News Releases May 20, 2019 Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum Additional Formats PDF Version May 14, 2019 Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights Additional Formats PDF Version April 10, 2019 Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer Additional Formats PDF Version March 28, 2019 Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment Additional Formats PDF Version March 27, 2019 Phio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights Additional Formats PDF Version March 25, 2019 Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019 Additional Formats PDF Version February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
Investor Relations News Releases News Releases May 20, 2019 Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum Additional Formats PDF Version May 14, 2019 Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights Additional Formats PDF Version April 10, 2019 Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer Additional Formats PDF Version March 28, 2019 Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment Additional Formats PDF Version March 27, 2019 Phio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights Additional Formats PDF Version March 25, 2019 Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019 Additional Formats PDF Version February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version Print Page Email Page RSS Feeds Email Alerts IR Contact Share
News Releases May 20, 2019 Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum Additional Formats PDF Version May 14, 2019 Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights Additional Formats PDF Version April 10, 2019 Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer Additional Formats PDF Version March 28, 2019 Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment Additional Formats PDF Version March 27, 2019 Phio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights Additional Formats PDF Version March 25, 2019 Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019 Additional Formats PDF Version February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version
May 20, 2019 Phio Pharmaceuticals to Present at Sachs Associates 5th Annual Immuno-Oncology BD&L and Investment Forum Additional Formats PDF Version
May 14, 2019 Phio Pharmaceuticals Reports First Quarter 2019 Financial Results and Corporate Highlights Additional Formats PDF Version
April 10, 2019 Phio Pharmaceuticals Appoints Dr. John Barrett as Chief Development Officer Additional Formats PDF Version
March 28, 2019 Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem's oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment Additional Formats PDF Version
March 27, 2019 Phio Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Corporate Highlights Additional Formats PDF Version
March 25, 2019 Phio Pharmaceuticals to Present Poster on the Use of Self-Delivering RNAi in Immuno-oncology at the AACR Annual Meeting 2019 Additional Formats PDF Version
February 15, 2019 Phio Pharmaceuticals Appoints Gerrit Dispersyn as New Chief Executive Officer Effective March 1 Additional Formats PDF Version
December 18, 2018 Phio Pharmaceuticals to Present at Biotech Showcase™ 2019 in San Francisco Additional Formats PDF Version
December 4, 2018 Phio Pharmaceuticals to Present at the Tumor Targeted Lymphocytes Summit in Boston on December 13 Additional Formats PDF Version
November 19, 2018 RXi Pharmaceuticals Corporation Changes Name to Phio Pharmaceuticals Corp. Additional Formats PDF Version
November 14, 2018 RXi Pharmaceuticals Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version
November 7, 2018 RXi Pharmaceuticals to Present New Data Demonstrating the Ability of sd-rxRNA to Enhance NK Cell Activity for Adoptive Cell Transfer at SITC 2018 Additional Formats PDF Version
November 6, 2018 RXi Pharmaceuticals to Webcast Third Quarter 2018 Financial Results on Wednesday, November 14, 2018 Additional Formats PDF Version
October 3, 2018 RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering Additional Formats PDF Version
October 1, 2018 RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering Additional Formats PDF Version
September 26, 2018 RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference Additional Formats PDF Version
August 28, 2018 RXi Pharmaceuticals to Present at the 20th Annual Rodman & Renshaw Global Investment Conference Additional Formats PDF Version
August 15, 2018 RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors Additional Formats PDF Version
August 14, 2018 RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights Additional Formats PDF Version
August 7, 2018 RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018 Additional Formats PDF Version
August 2, 2018 RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan Additional Formats PDF Version
August 1, 2018 RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring Additional Formats PDF Version
